A next-gen TOR inhibitor used in cancer research unexpectedly extends lifespan in yeast through a newly uncovered metabolic feedback loop.
A cancer drug designed to shut down tumor growth has revealed an unexpected additional effect: slowing the cellular aging process. Researchers at Queen Mary University of London have discovered that rapalink-1, a next-generation inhibitor of the Target of Rapamycin (TOR) pathway, can significantly extend the lifespan of fission yeast, one of the most widely used organisms for studying basic biology.
The findings, published in Communications Biology, underscore how deeply metabolism, nutrition, and cell growth are intertwined, and how a treatment built for one field (oncology) may hold promise for another (longevity science) [1].
For investors tracking the intersection of antiaging therapeutics, metabolic rewiring and cancer biotech, the latest findings represent a meaningful scientific signal.
The TOR pathway is one of the most studied longevity regulators in biology. Present in species from yeast to humans, TOR helps cells decide when to grow and when to conserve resources.
When TOR is highly active, cells prioritize growth and reproduction. When TOR is dialed down – through fasting, stress or drugs like rapamycin – cells shift toward repair and maintenance, a shift long associated with extended lifespan in animals.
Because TOR is also central to cancer metabolism, TOR inhibitors such as rapamycin and rapalink-1 have been extensively explored for the treatment of tumors. But researchers increasingly believe that precisely modulating TOR, rather than shutting it off completely, could be a key to healthy aging.
Rapalink-1, an advanced molecule currently under study for oncology, targets TORC1, the growth-promoting branch of the TOR pathway. The new research shows that this drug does more than suppress growth signals: it extends the chronological lifespan of yeast, meaning the cells stay functional and healthier for longer.
In the process, the researchers found something surprising: a previously unknown metabolic feedback loop involving enzymes called agmatinases. These enzymes convert the metabolite agmatine into polyamines, small molecules essential for cell survival.
When agmatinase activity was blocked, yeast cells grew more quickly but aged faster, revealing a fundamental biological trade-off: short-term growth vs. long-term survival.
Even more strikingly, providing yeast with agmatine or its downstream metabolite, putrescine, helped extend lifespan under certain conditions. This suggests that both pharmaceuticals and natural metabolites may influence aging through shared molecular nodes.
“By showing that agmatinases are essential for healthy aging, we’ve uncovered a new layer of metabolic control over TOR – one that may be conserved in humans,” said Dr Charalampos Rallis, one of the study authors [2].
Because the gut microbiome produces agmatine and is abundant in certain foods, this discovery may help explain why nutrition, diet quality, and microbial activity have measurable effects on human aging and metabolic health.
Rallis emphasized caution, however, noting that agmatine supplements already exist on the commercial market: “We should be cautious about consuming agmatine for growth or longevity purposes.”
He added that the benefits appear only when specific metabolic pathways are intact, and that agmatine “does not always promote beneficial effects as it can contribute to certain pathologies.”
For investors in longevity biotech, this study expands TOR biology in several important ways:
- Validated pathway: TOR remains one of the most potent and reproducible targets for lifespan extension across species.
- Drug + diet synergy: The research hints that future therapies may combine TOR inhibitors with nutritional or microbiome-based interventions.
- Cancer-longevity crossover: A cancer drug producing measurable longevity effects highlights the increasingly shared landscape between oncology and anti-aging therapeutics.
- New metabolic nodes: Agmatinases and polyamine metabolism may emerge as targets for next-gen interventions.
The team’s genome-wide screens also revealed additional genes and pathways linked to TOR activity but not yet explored in aging research, a potential roadmap for future drug discovery.
Interest in molecules such as spermidine, metformin and microbiome-derived metabolites continues to grow as researchers map how metabolic circuits govern aging. The discovery that rapalink-1 can manipulate these circuits strengthens the case for therapies that subtly tune cellular metabolism rather than simply blocking disease pathways.
Although these findings start in yeast, they challenge a long-held assumption in biotech that longevity breakthroughs must come from drugs built for aging, not repurposed from oncology.
Rapalink-1 shows that the most powerful levers of lifespan may already be sitting in cancer pipelines, hiding in plain sight. Suppose this metabolic feedback loop holds up in higher organisms. In that case, it may force the industry to rethink where the next generation of longevity drugs will actually come from.
[1] https://www.nature.com/articles/s42003-025-08731-3
[2] https://scitechdaily.com/next-generation-cancer-drug-found-to-slow-aging-and-boost-longevity-in-lab-study/
